A patient who has been stable on a maintenance dose for months without gastrointestinal symptoms may have lower practical risk than a patient who recently started therapy, recently increased the dose, has nausea or vomiting, or has known diabetic gastroparesis
Last month, a key patent on semaglutide the GLP-1 sold as Ozempic, Wegovy, and Rybelsus expired in India, a country known for making affordable drugs at scale
As awareness spreads, demand for GLP-1s in weight loss and diabetes care is expected to keep climbing
The microbiota: a key regulator of health, productivity, and reproductive success in mammals
The initial quality becomes meaningless
Schedule an introductory consultation to learn more about your proven, safe weight loss options